Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...
Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...
Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for ...
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Sept. 2, 2025 /PRNewswire/ -- September is Pulmonary Fibrosis Awareness Month, and the American Lung ...
Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
Credit: Getty Images. The first step in diagnosing idiopathic pulmonary fibrosis is ruling out other known causes of interstitial lung disease. Making an accurate diagnosis of IPF is critical because ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.
CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...
Rheumatoid arthritis (RA) was causally linked to the development of idiopathic pulmonary fibrosis, with shared plasma factors CC motif chemokine ligand 2 (CCL2) and CXC motif chemokine ligand 2 (CXCL2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results